Cargando…
Navigating the complex landscape of benzodiazepine- and Z-drug diversity: insights from comprehensive FDA adverse event reporting system analysis and beyond
INTRODUCTION: Medications which target benzodiazepine (BZD) binding sites of GABAA receptors (GABAARs) have been in widespread use since the nineteen-sixties. They carry labels as anxiolytics, hypnotics or antiepileptics. All benzodiazepines and several nonbenzodiazepine Z-drugs share high affinity...
Autores principales: | Koniuszewski, Filip, Vogel, Florian D., Dajić, Irena, Seidel, Thomas, Kunze, Markus, Willeit, Matthäus, Ernst, Margot |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345211/ https://www.ncbi.nlm.nih.gov/pubmed/37457785 http://dx.doi.org/10.3389/fpsyt.2023.1188101 |
Ejemplares similares
-
Tricyclic antipsychotics and antidepressants can inhibit α5‐containing GABA(A) receptors by two distinct mechanisms
por: Bampali, Konstantina, et al.
Publicado: (2022) -
Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health
por: McHugh, R. Kathryn, et al.
Publicado: (2023) -
Cys-loop receptors on cannabinoids: All high?
por: Schmiedhofer, Philip, et al.
Publicado: (2022) -
Structure-Guided Computational Methods Predict Multiple Distinct Binding Modes for Pyrazoloquinolinones in GABA(A) Receptors
por: Fabjan, Jure, et al.
Publicado: (2021) -
Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification
por: Benini, Anna, et al.
Publicado: (2021)